Details of the sales branch of Wuhan Yuanda Pharmaceutical Group Co., Ltd.

According to the business and development needs of Wuhan Yuanda Pharmaceutical Group Company, the company has newly established a wholly-owned subsidiary with independent legal personality, "Wuhan Yuanda Pharmaceutical Group Sales Co., Ltd." (hereinafter referred to as "Sales Co., Ltd." ), the business scope of the Sales Co., Ltd. is: Chinese patent medicines, chemical raw materials, chemical pharmaceutical preparations, antibiotic preparations, and biochemical drugs. The legal representative of the Sales Co., Ltd. is Xie Guofan, and the general manager is Shi Xiaofeng.

All personnel and business of the original "Sales Branch of Wuhan Yuanda Pharmaceutical Group Co., Ltd." (hereinafter referred to as the "Sales Branch") will be transferred to the Sales Co., Ltd. starting from January 1, 2011. After more than 60 years of development, Wuhan Yuanda Pharmaceutical has become a modern Sino-foreign pharmaceutical joint venture with a registered capital of 85 million yuan, an area of ??300 acres, and a construction area of ??96,000 square meters. The company's main products include pharmaceutical preparations, pharmaceutical raw materials and intermediates, with annual sales revenue of 400 million yuan and annual export earnings of US$15 million. It has an annual production capacity of 200 million liquid preparations, more than 4 billion solid preparations, and more than 4,000 tons of APIs. It is a designated enterprise for national war readiness reserves of emergency medicines and narcotics.

The company's main products are pharmaceutical raw materials, intermediates and pharmaceutical preparations. It mainly produces more than 30 APIs and intermediates such as metamizole, metronidazole, enoxacin, pirenoxine sodium, tiopronin, and norrenin, among which norrenin has been certified by the US FDA. The company has independently developed 3 national Class II new drugs and 9 Class IV new drugs, and was the first to launch the national new cardiovascular drug Xinweining (Tirofiban Hydrochloride Sodium Chloride Injection). The company has now formed new specialties such as antibacterial drugs with the Noga series as the core, cardiovascular drugs with Xinweining as the core, liver disease drugs with Noonin as the core, and ophthalmic drugs with Belonitin and Jingming as the core. The product group has become a key "high-tech enterprise" in the Torch Program of the Ministry of Science and Technology. Wuhan Yuanda Pharmaceutical Group Sales Branch is the sales platform of China Yuanda Pharmaceutical Division and is responsible for promoting the professional pharmaceutical products of its subsidiaries. Wuhan Tiantianming Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Wuhan Yuanda Pharmaceutical Group. Founded in 1996, it is a national key ophthalmic drug production base and a high-tech enterprise supported by the state. Wuhan Yuanda Sales Branch is a professional sales company affiliated to Wuhan Yuanda Pharmaceutical Group, focusing on ophthalmology and cardiovascular products! The company has a strong and competitive professional sales team, a marketing network covering the whole country, and offices in all provinces, cities and autonomous regions except Taiwan. The company's product line is extensive and far-reaching, with new specialty product groups as its core, such as ophthalmic product lines such as Benetide, Noga, and Tiantianming series, as well as cardiovascular product lines. It has 6 national Class II new drugs, 11 Class IV new drugs, 8 new products about to be launched, and 16 varieties under research. The ENT products alone include 22 varieties in 5 categories, and the products are unique.

Among them, the famous brand-name product Binaide series has created a classic in the history of cataract medication. It has been recorded in history and has been enduring for a long time. It has the exclusive right to name its trademark and has won many provincial silver medals. In 2003, the new products Bingzhen Qingmu and Bingzhen Eliminating Eye Drops were launched, both of which obtained the drug approval number "quasi" and entered the over-the-counter drug (OTC Class A Chinese medicine preparations) drug catalog, which was deeply recognized by consumers.

In 2004, "Xinweining" (Tirofiban Hydrochloride Sodium Chloride Injection), an internationally advanced new platelet membrane glycoprotein GPIIb/IIIa receptor antagonist for the treatment of cardiovascular diseases, was launched. Officially launched on the market, it has filled the gap in domestic antiplatelet preparations. In March 2010, Wuhan Yuanda fully acquired Hubei Ruizhu Pharmaceutical

The sales branch of Wuhan Yuanda Pharmaceutical Group is the sales platform of China Yuanda Pharmaceutical Division and is responsible for promoting the professional pharmaceutical products of its subsidiaries. Wuhan Tiantianming Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Wuhan Yuanda Pharmaceutical Group. Founded in 1996, it is a national key ophthalmic drug production base and a high-tech enterprise supported by the state.

In 2010, Wuhan Yuanda wholly acquired Hubei Ruizhu Pharmaceutical. The company owns the eye gel production line of the Italian AXOMATIC company and the "three-in-one" eye drops production line of the American WEILER company, which are world-class production equipment. Produces ophthalmic gels and preservative-free daily dose eye drops. After the merger, Wuhan Yuanda Tiantianming Pharmaceutical has always regarded seizing the commanding heights of science and technology as the foundation of its development. In order to ensure that the technology is forward-looking, it has established a fast-running, virtuous cycle of scientific and technological innovation system from research to development and production.

Since the integration and re-establishment in 2008, the company has carried the corporate philosophy of "traveling around the world, health is the most important", with the lofty vision of "the world is brighter every day because of us" and "life is brighter every day because of us" , with "Tiantianming" as the brand integrated promotion, determined to wholeheartedly engage in the research and development, production and sales of drugs in the field of ENT and cardiovascular fields, and is committed to becoming an expert in the field of ENT and cardiovascular fields in China.

Wuhan Yuanda adheres to the principle of helping the world and firmly believes that the greater the ability, the greater the responsibility. Every day, we measure the world with our steps, and the steps under our feet are firmer and faster, making continuous contributions to the bright and healthy cause of all mankind. contribution!